FOXO4-DRI
D-retro-inverso peptide. Disrupts FOXO4-p53 interaction in senescent cells, triggering selective apoptosis (senolytic mechanism).
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Erasmus MC (Baar et al. 2017) showed targeted clearance of senescent cells in aged mice with reduced frailty markers. No human trials. Often cited as the prototype peptide senolytic — but the Erasmus group has not advanced human studies as of 2025.
Pure research compound. No human safety data. Self-administering a senolytic without medical oversight carries unknown systemic risks. Most products sold as 'FOXO4-DRI' to consumers are unverifiable in identity.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
FOXO4-DRI — primary mechanism: d-retro-inverso peptide. disrupts foxo4-p53 interaction in senescent cells, triggering selective apoptosis (senolytic mechanism).
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: varies — research only · research-only protocols
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Pure research compound — no clinical use